Drug delivery using novel nanoplexes against a Salmonella mouse infection model
Source abstract
Abstract
A novel methodology for incorporating gentamicin into macromolecular complexes with anionic homo- and block copolymers via cooperative electrostatic interactions is described. Block copolymers of poly(ethylene oxide-b-sodium acrylate) (PEO-b-PAA− +Na) or poly(ethylene oxide-b-sodium methacrylate) (PEO-b-PMA− +Na) were blended with PAA− Na+ and complexed with the polycationic antibiotic gentamicin. Gentamicin nanoplexes made with PEO-b-PMA− +Na/PAA− +Na (PMPG) and analogous nanoplexes with PEO-b-PAA− +Na/PAA− +Na (PAPG) had mean intensity average diameters of 120 and 90 nm, zeta potentials of −17 and −11 mv, and incorporated 26% and 23% by weight of gentamicin, respectively. Gentamicin release rates at physiological pH from nanoplexes were relatively slow. PAPG and PMPG as drug delivery systems for treating murine salmonellosis at doses similar to the free gentamicin experiments resulted in reduced numbers of viable bacteria in the liver and spleen. Polymeric nanoplexes developed by this methodology can potentially improve targeting of intracellular pathogens.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Azamian BR, Coleman KS, Davis JJ, Hanson N, Green ML (2002) Directly observed covalent coupling of quantum dots to single-wall carbon nanotubes. Chem Commun (Camb) 4:366–367. doi: 10.1039/b110690b10.1039/b110690b ↗
2. Cordeiro C, Wiseman DJ, Lutwyche P, Uh M, Evans JC, Finlay BB, Webb MS (2000) Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model. Antimicrob Agents Chemother 44:533–539. doi: 10.1128/AAC.44.3.533-539.200010.1128/AAC.44.3.533-539.2000 ↗
3. Davaran S, Rashidi MR, Pourabbas B, Dadashzadeh M, Haghshenas NM (2006) Adriamycin release from poly(lactide-co-glycolide)-polyethylene glycol nanoparticles: synthesis and in vitro characterization. Int J Nanomedicine 1:535–539. doi: 10.2147/nano.2006.1.4.53510.2147/nano.2006.1.4.535 ↗
4. Ellbogen MH, Olsen KM, Gentry-Nielsen MJ, Preheim LC (2003) Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 51:83–91. doi: 10.1093/jac/dkg02410.1093/jac/dkg024 ↗
5. Galdiero F, Carratelli CR, Nuzzo I, Bentivoglio C, De Martino L, Folgore A, Galdiero M (1995) Enhanced cellular response in mice treated with a Brucella antigen-liposome mixture. FEMS Immunol Med Microbiol 10:235–243. doi: 10.1111/j.1574-695X.1995.tb00038.x10.1111/j.1574-695X.1995.tb00038.x ↗
6. Gamazo C, Lecaroz MC, Prior S, Vitas AI, Campanero MA, Irache JM, Blanco-Prieto MJ (2006) Chemical biological factors in the control of Brucellosis. Curr Drug Deliv 3:359–365. doi: 10.2174/15672010677855903810.2174/156720106778559038 ↗
7. Gaspar MM, Cruz A, Penha AF, Reymao J, Sousa AC, Eleuterio CV, Domingues SA, Fraga AG, Filho AL, Cruz ME, Pedrosa J (2008) Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents 31:37–45. doi: 10.1016/j.ijantimicag.2007.08.00810.1016/j.ijantimicag.2007.08.008 ↗
8. Gupta K, Ganguli M, Pasha S, Maiti S (2006) Nanoparticle formation from poly(acrylic acid) oppositely charged peptides. Biophys Chem 119:303–306. doi: 10.1016/j.bpc.2005.09.01310.1016/j.bpc.2005.09.013 ↗
9. Hou SCEL, Taton D, Gnanou Y (2003) Synthesis of water-soluble star-block dendrimer-like copolymers based on poly(ethylene oxide) -poly(acrylic acid). Macromolecules 36:3874–3881. doi: 10.1021/ma021565d10.1021/ma021565d ↗
10. Lecaroz C, Blanco-Prieto MJ, Burrell MA, Gamazo C (2006a) Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J Antimicrob Chemother 58:549–556. doi: 10.1093/jac/dkl25710.1093/jac/dkl257 ↗
11. Lecaroz C, Campanero MA, Gamazo C, Blanco-Prieto MJ (2006b) Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method. J Antimicrob Chemother 58:557–563. doi: 10.1093/jac/dkl25810.1093/jac/dkl258 ↗
12. Lecaroz C, Gamazo C, Blanco-Prieto MJ (2006c) Nanocarriers with gentamicin to treat intracellular pathogens. J Nanosci Nanotechnol 6:3296–3302. doi: 10.1166/jnn.2006.47810.1166/jnn.2006.478 ↗
13. Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H, Gamazo C (2007) Poly(DL-lactide-co-glycolide) particles containing gentamicin: pharmacokinetics, pharmacodynamics in Brucella melitensis-infected mice. Antimicrob Agents Chemother 51:1185–1190. doi: 10.1128/AAC.00809-0610.1128/AAC.00809-06 ↗
14. Lutwyche P, Cordeiro C, Wiseman DJ, St-Louis M, Uh M, Hope MJ, Webb MS, Finlay BB (1998) Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother 42(10):2511–252010.1128/AAC.42.10.2511 ↗
15. Monack DM, Bouley DM, Falkow S (2004) Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice can be reactivated by IFN-gamma neutralization. J Exp Med 199:231–241. doi: 10.1084/jem.2003131910.1084/jem.20031319 ↗
16. Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J (2008) Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. Anticancer Res 28:1329–1334
17. Page-Clisson ME, Pinto-Alphary H, Chachaty E, Couvreur P, Remont A (1998) Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharm Res 15:544–549. doi: 10.1023/A:101192160896410.1023/A:1011921608964 ↗
18. Pan J, Zhao M, Liu Y, Wang B, Mi L, Yang L (2008) Development of a new poly(ethylene glycol)-graft-poly(d,l-lactic acid) as potential drug carriers. J Biomed Mater Res A 89(A) 160–16710.1002/jbm.a.31965 ↗
19. Pandey R, Khuller GK (2007) Nanoparticle-based oral drug delivery system for an injectable antibiotic—streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 53:437–441. doi: 10.1159/00011000910.1159/000110009 ↗
20. Prior S, Ger B, Irache JM, Gamazo C (2005) Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J Antimicrob Chemother 55:1032–1036. doi: 10.1093/jac/dki14410.1093/jac/dki144 ↗
21. Ristuccia AM, Cunha BA (1982) The aminoglycosides. Med Clin North Am 66:303–31210.1016/S0025-7125(16)31462-6 ↗
22. Rudt S, Muller RH (1993) In vitro phagocytosis assay of nano-microparticles by chemiluminescense III: Uptake of differently sized surface-modified particles, its correlation to particle properties, in vivo distribution. Eur J Pharm Sci 1:31–39. doi: 10.1016/0928-0987(93)90015-310.1016/0928-0987(93)90015-3 ↗
23. Seleem MN, Boyle SM, Sriranganathan N (2008) Brucella: a pathogen without classic virulence genes. Vet Microbiol 129:1–14. doi: 10.1016/j.vetmic.2007.11.02310.1016/j.vetmic.2007.11.023 ↗
24. Smyth Templeton N (2003) Cationic liposomes as in vivo delivery vehicles. Curr Med Chem 10:1279–1287. doi: 10.2174/092986703345742110.2174/0929867033457421 ↗
25. Steinberg BE, Grinstein S (2008) Pathogen destruction versus intracellular survival: the role of lipids as phagosomal fate determinants. J Clin Invest 118:2002–2011. doi: 10.1172/JCI3543310.1172/JCI35433 ↗
26. Sukupolvi S, Edelstein A, Rhen M, Normark SJ, Pfeifer JD (1997) Development of a murine model of chronic Salmonella infection. Infect Immun 65:838–84210.1128/IAI.65.2.838-842.1997 ↗
27. Vonarbourg A, Passirani C, Saulnier P, Benoit JP (2006) Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27:4356–4373. doi: 10.1016/j.biomaterials.2006.03.03910.1016/j.biomaterials.2006.03.039 ↗
28. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD (2007a) Enhanced solubility-stability of PEGylated liposomal paclitaxel: in vitro–in vivo evaluation. Int J Pharm 338:317–326. doi: 10.1016/j.ijpharm.2007.02.01110.1016/j.ijpharm.2007.02.011 ↗
29. Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, Kim DD (2007b) Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 14:301–308. doi: 10.1080/1071754060109879910.1080/10717540601098799 ↗